HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in Am J Health-Syst Pharm Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kasbekar, N. Search for Related Content PubMed PubMed Citation Articles by Kasbekar, N.

NISHAMINY KASBEKAR, PHARM.D., is Clinical Specialist, Infectious Diseases, and Director, Medication Management and Utilization, Department of Pharmacy, University of Pennsylvania Presbyterian Medical Center, 51 North 39th Street, Philadelphia, PA 19104 (nishaminy.kasbekar{at}uphs.upenn.edu).

Purpose. The pharmacology, spectrum of activity, pharmacokinetics, clinical efficacy, adverse events, dosage and administration, drug interactions, and place in therapy of tigecycline are reviewed. Summary. Tigecycline is the first of a new class of antimicrobials, the glycylcyclines, to receive approved labeling from the Food and Drug Administration. Similar to tetracyclines, glycylcyclines contain the central four-ring carbocyclic skeleton, with a substitution at the D-9 position. This substitution confers expanded broad-spectrum activity and defense against antimicrobial efflux pumps and ribosomal protection mechanisms. Tigecycline covers a broad spectrum of gram-positive (including resistant isolates), gram-negative (including extended-spectrum ß-lactamase producing organisms), and anaerobic pathogens. It does not exhibit activity against Pseudomonas aeruginosa and Proteus species. Clinical efficacy has been demonstrated in complicated skin and skin structure infections and intraabdominal infections. Tigecycline is administered intravenously and exhibits linear pharmacokinetics. The drug does not undergo extensive metabolism and works independently of the cytochrome P-450 isoenzyme system and therefore does not affect medications metabolized by these enzymes. Tigecycline is administered as a 100-mg i.v. loading dose followed by 50 mg i.v. every 12 hours. Hepatic dosage adjustment is necessary for severe disease; however, no dosage adjustments are necessary for patients with renal impairment. Conclusion. Tigecycline is an alternative agent available for the treatment of resistant gram-negative and gram-positive infections, especially in patients with a history of a penicillin allergy or antimicrobial-related toxicities. Index terms: Antiinfective agents; Dosage; Drug administration; Drug interactions; Infections; Kidney failure; Liver diseases; Mechanism of action; Metabolism; Pharmacokinetics; Spectrum microbial; Tigecycline; Toxicity

 

Related articles in Am J Health-Syst Pharm:

Tigecycline: Place in therapy and important considerations

James C. Garrelts and Todd Schroeder
Am J Health-Syst Pharm 2006 63: 1233. [Full Text]  

This article has been cited by other articles:

				J. C. Garrelts and T. Schroeder Tigecycline: Place in therapy and important considerations. Am. J. Health Syst. Pharm., July 1, 2006; 63(13): 1233 - 1233. [Full Text] [PDF]